Denial Rates Fell in 2026, but Payer Takebacks Kept Provider Cash From Improving

Revenue cycle teams spent the first half of 2026 doing what they were asked to do, and denial rates came down. The cash did not follow. A Kodiak Solutions analysis of claims from more than 2,300 hospitals and 375,000 physicians found that providers reduced both initial and final denial rates compared with the first half of 2025, yet the improvement did not lead to better cash performance. Insurers recouped more money from claims they had already paid.

For CFOs at ambulatory surgery centers and multi-site outpatient groups, that finding changes what the scoreboard means. The dispute between payers and providers over what a claim is worth has moved downstream, past the point of payment, where a paid claim can still be reopened and taken back. The arrangement is broken, it shows no sign of going away, and providers should not have to fund it from the resources that pay for patient care. The durable fix is to settle the rules once, in a single source of truth both sides accept before the claim is filed, so that a paid claim stays paid.

Kodiak Data Shows Takebacks Rising Across Every Payer Category

Kodiak, which published the findings on Sept. 15, 2026, measured takebacks equal to 1.57% of accounts receivable in the first half of 2026, up from 1.38% a year earlier, a 13.8% increase. The rise held across every payer and patient setting in the analysis. At the same time, provider recoveries after payment fell to 2.21% of accounts receivable from 2.48%, a 12.2% decrease.

The gap was widest in Medicare Advantage. Even under the same coverage rules, insurers running Medicare Advantage plans showed higher initial and final denial rates than traditional Medicare and more than double the percentage of takebacks. Commercial plans followed a similar pattern: the initial denial rate fell, but the final denial rate rose 9.1% to 2.89% of accounts receivable, and commercial takebacks increased 12% to 2.25%.

"Revenue cycle leaders must ask themselves three questions: How much did we collect? How hard did we have to work to collect those funds? And, crucially, how much of what we collected did we keep?" said Matt Szaflarski, vice president of revenue cycle intelligence at Kodiak.

A Takeback Reaches Cash Already on the Books

A front-end denial delays payment. A takeback reverses a payment the provider has already posted and reconciled, and the provider must then defend a claim the payer previously accepted. For physician-owned surgery centers, that can mean revisiting revenue that has already flowed through to distributions.

The Kodiak numbers show both sides of that squeeze moving the wrong way at once. More paid dollars are being pulled back, and a smaller share is coming back through appeals and disputes. A lower denial rate on the front end does little for margin if the dollars it protects leave later.

Insurer Earnings Show the Value of Every Ratio Point

UnitedHealth Group's third-quarter 2026 results show how much is at stake on the payer side. Revenue slipped to $112.7 billion from $113.2 billion a year earlier, while earnings from operations rose to $6.6 billion from $4.3 billion and adjusted earnings per share climbed to $4.69 from $2.92. The medical care ratio fell to 88.4% from 89.9%, which the company attributed to medical cost management initiatives, benefit design changes, pricing discipline and care delivery enhancements. The quarter also included $610 million of favorable prior period reserve development.

The release does not break out post-payment recoveries, and nothing in it ties the lower ratio to takebacks. The arithmetic of the incentive is still plain. With about $87.1 billion in quarterly premiums, each percentage point of medical care ratio is worth roughly $870 million to the company in a single quarter.

Lab Claims Show How Automated Review Changes the Economics

Diagnostic laboratories often see payer behavior shifts early. XiFin's 2026 Payor Denial Impact Report, based on more than 30 million claims, found that denials of clinical laboratory, molecular diagnostic and genomics claims rose to 11.2% in 2025 from 8.0% the year before, a 40% jump that erased two years of improvement. Prior authorization denials for genetic and molecular tests more than doubled to 27.6% of all denials from 13.1% in 2021, and XiFin reported that denials have shifted toward "technical" and "payment integrity" categories such as code mismatches and documentation deficiencies.

Read alongside Kodiak, the pattern is consistent. In both data sets, the dispute moved to a later or less visible stage of the claim.

Speed is part of the story. "Health plans have modernized how they review claims. Decisions now happen in a fraction of a second with payors' use of AI," said Kyle Fetter, chief operating officer of XiFin. A 2025 National Association of Insurance Commissioners survey found that 84% of the 93 health insurers it surveyed use AI or machine learning in some capacity. An automated review costs a payer little to issue, while every response costs the provider staff time.

Federal Prior Authorization Rules Stop Short of Paid Claims

Operational provisions of the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) took effect Jan. 1, 2026. Medicare Advantage organizations and Medicaid and CHIP programs, including their managed care plans, must return expedited prior authorization decisions within 72 hours and standard decisions within seven calendar days. All payers covered by the rule, including Qualified Health Plan issuers on the federal exchanges, must give a specific reason for each denial and publicly report prior authorization metrics.

Those protections govern decisions made before care is delivered. Federal prior authorization reform does not prevent an insurer from retroactively denying payment for care it approved in advance, which leaves the post-payment stage governed largely by contract terms and plan policies that vary from payer to payer.

The Case for Rules Agreed Before the Claim

Kodiak's own conclusion was that revenue cycle performance should be measured by the final revenue yield from claims. Takebacks are among the clearest signs that payer and provider are working from different versions of the rules: a claim satisfied one reading when it was paid and another when it was reviewed. When coverage criteria, documentation requirements, authorization status and contract terms sit in one shared record that both parties accept before the claim is filed, a payment can be final in practice as well as on paper.

Fetter made a related point about denials that are routinely overturned. "When a provider keeps winning the same kinds of appeals, it can be a sign that those claims should never have been denied in the first place," he said. "Often, the claims met the payor's policy, medical necessity, and documentation requirements all along."

For multi-site surgical and procedural groups, the stakes come down to capacity. Every dollar recouped after the fact, and every hour spent defending it, comes out of the same budget that staffs operating rooms and supports clinicians. Exactrx was built as an AI-native revenue cycle company on the premise that payer rules should be reconciled by software before a claim goes out and tracked through to the cash a provider keeps, so that patient care never becomes the price of a broken system.